BioXcel regains compliance with Nasdaq listing rule
Source: SeekingAlpha
2025-09-18 07:41:38 ET
More on BioXcel Therapeutics
- BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)
- BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call - Slideshow
- BioXcel whipsaws after late-stage trial win for lead asset
- Seeking Alpha’s Quant Rating on BioXcel Therapeutics
- Historical earnings data for BioXcel Therapeutics
Read the full article on Seeking Alpha
For further details see:
BioXcel regains compliance with Nasdaq listing rule
BioXcel Therapeutics Inc.
NASDAQ: BTAI
BTAI Trading
-3.25% G/L:
$1.5189 Last:
384,767 Volume:
$1.57 Open:
BTAI Latest News
March 11, 2026 04:20:00 pm
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
March 10, 2026 02:36:00 pm
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
BTAI Stock Data
$36,631,397
21,060,320
0.54%
17
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
